A pharmaceutical company, Pharmacy Plus has launched Duostam, an advanced treatment for Benign Prostatic Hyperplasia (BPH), also known as prostate enlargement.
BPH is a non-cancerous condition involving an increase in the size of the prostate gland due to cellular growth.
Speaking at the 97th Pharmaceutical Society of Nigeria Conference held in Uyo, Akwa-Ibom State Capital, Consultant Urologist University of Nigeria, Nsukka, Prof Ikenna Nnabugwu, highlighted that the prostate is a major contributor to Lower Urinary Tract Symptoms (LUTS) in ageing men, with a prevalence of LUTS/BPH reaching approximately 20 per cent in men over 40 years old.
He explained that in response to this significant health concern, Pharmacy Plus has introduced innovative Duostam as a targeted solution for BPH treatment.
Nnabugwu said Duostam offers numerous benefits, including, relief from LUTS, improved patient-reported quality of life (QoL), slower disease progression, reduced risk of acute urinary retention (AUR), and reduced risk of bleeding from an enlarged prostate.
The Managing Director of Pharmacy Plus, Chukwuemeka Obi, stated that as a research-driven pharmaceutical company, the company is committed to providing effective treatment options for patients.
He assured that Duostam is safe for use, with clinical studies confirming its efficacy when used as prescribed.
SOURCE: GUARDIAN NEWSPAPER